July 19, 2021
Takeda Pharmaceutical’s NEDD8-activating enzyme inhibitor pevonedistat is expected to be the first drug to obtain designation under the sakigake fast-track system since the scheme earned full legal backing last September. At its meeting on July 30, the Pharmaceutical Affairs and...read more